Cargando…

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer

Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to fur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mabuchi, Seiji, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265244/ https://www.ncbi.nlm.nih.gov/pubmed/22312560 http://dx.doi.org/10.1155/2011/963159

Ejemplares similares

Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors
por: Fujiwara, Masateru, et al.
Publicado: (2015)

Hypomagnesemia because of nedaplatin for cervical cancer: A case report
por: Komoda, Jun, et al.
Publicado: (2023)

Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters
por: Isohashi, Fumiaki, et al.
Publicado: (2015)

Radiosensitization Effect of Nedaplatin on Nasopharyngeal Carcinoma Cells in Different Status of Epstein-Barr Virus Infection
por: Yin, Li, et al.
Publicado: (2014)

Nedaplatin: a cisplatin derivative in cancer chemotherapy
por: Shimada, Muneaki, et al.
Publicado: (2013)

Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer
por: Zhang, Yue, et al.
Publicado: (2023)

Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and Histopathological Characteristics
por: Uehara, Takeki, et al.
Publicado: (2011)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
por: Mabuchi, Seiji, et al.
Publicado: (2017)

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
por: Yang, X., et al.
Publicado: (2022)

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
por: Mabuchi, Seiji, et al.
Publicado: (2016)

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers
por: Mabuchi, Seiji, et al.
Publicado: (2021)

Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis
por: Takekuma, Munetaka, et al.
Publicado: (2018)

Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors
por: Matsuo, Koji, et al.
Publicado: (2015)

Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma
por: Yokoi, Eriko, et al.
Publicado: (2017)

Combination Chemotherapy with Nedaplatin and Cyclophosphamide in Human Ovarian Cancer Model
por: Uchida, Naomi, et al.
Publicado: (1999)

HPV and radiosensitivity of cervical cancer: a narrative review
por: Huang, Yue, et al.
Publicado: (2022)

Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice
por: Shimura, Kotaro, et al.
Publicado: (2013)

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
por: He, Shasha, et al.
Publicado: (2022)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

Phase I trial of nedaplatin and S-1 in patients with advanced squamous cell lung cancer
por: Kanaji, Nobuhiro, et al.
Publicado: (2020)

Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer
por: Alcorn, Sara, et al.
Publicado: (2013)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Preclinical in vivo Antitumor Efficacy of Nedaplatin with Gemcitabine against Human Lung Cancer
por: Matsumoto, Mitsunobu, et al.
Publicado: (2001)

Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report
por: Hirakawa, Hiroyuki, et al.
Publicado: (2017)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review
por: Kozasa, Katsumi, et al.
Publicado: (2017)

Case Report: Etoposide-nedaplatin induced rhabdomyolysis in a small cell lung cancer patient
por: Xu, Xiaohu, et al.
Publicado: (2023)

Novel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells
por: Song, Yanan, et al.
Publicado: (2016)

RETROSPECTIVE CASE SERIES OF 15 PATIENTS TREATED WITH CHEMORADIATION USING 5-FU AND NEDAPLATIN FOR GYNECOLOGICAL MALIGNANCY: WITH REGARD TO HEMOTOXICITY
por: ITOH, YOSHIYUKI, et al.
Publicado: (2014)

Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study
por: Ohnuma, Hiroyuki, et al.
Publicado: (2018)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer
por: Komura, Naoko, et al.
Publicado: (2019)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
por: Kawano, Mahiru, et al.
Publicado: (2015)

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy
por: Alhussan, Abdulaziz, et al.
Publicado: (2021)

Autophagy and radiosensitization in cancer
por: Sharma, Khushboo, et al.
Publicado: (2014)

The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review
por: Pepper, Niklas Benedikt, et al.
Publicado: (2022)

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
por: Kurata, T, et al.
Publicado: (2004)

Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells
por: Fahmy, Sherif Ashraf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_115rk65h2dsmpdejr20ele3s97